U.S. equities have shown significant resilience this year, remaining positive in the face of elevated Treasury yields, oil prices exceeding $100, persistent inflation, tariff uncertainties, and narrow market breadth. Following the Federal Reserve's rate hike in September, which tightened financial conditions, weaker job data has lowered expectations for another imminent increase. Despite these macroeconomic challenges, robust earnings and a resurgence in AI-driven tech strength have kept major indexes near record highs.
Read More
In this environment, selecting the right stock can be challenging. However, broker recommendations can simplify the process. Notable upgrades have been given to Dollar General Corporation (DG), Bristol-Myers Squibb Company (BMY), and Equinor ASA (EQNR).
Broker rating upgrades typically involve comprehensive research, including discussions with management, regulatory filings, earnings calls, channel checks, and industry analysis. Such thorough evaluations help analysts gauge a company's fundamentals alongside macro trends, competitive positioning, and peer performance.
An upgrade generally indicates a more optimistic outlook, often due to developments not yet reflected in existing consensus estimates or valuations. This can signal improving earnings expectations or shifts in investor sentiment. However, these upgrades should be assessed within the context of overall fundamentals and earnings trends to form a well-rounded investment approach.
To identify potential winning stocks, a screening strategy has been employed. This strategy highlights stocks that have experienced broker rating upgrades of 1% or more in the past four weeks, trade above $5, have an average 20-day trading volume greater than 100,000, hold a Zacks Rank of #1 (Strong Buy) or #2 (Buy), and possess a VGM Score of A or B.
Investors may find opportunities in these three stocks with upgraded broker ratings. Dollar General, based in Goodlettsville, TN, is a leading discount retailer known for its diverse product range that includes both national brands and private labels, generally priced lower than comparable items. DG’s earnings for fiscal 2027 are projected to grow by 15.9%, and it recently received a 3.2% upward revision in broker ratings.
Bristol-Myers Squibb, located in New Jersey, focuses on developing treatments for severe diseases, with product offerings spanning oncology, hematology, immunology, cardiovascular, and neuroscience. Earnings for the company are expected to rise by 12.4% in 2026, with broker ratings also seeing a 3.2% increase.
Equinor ASA, an integrated energy company headquartered in Stavanger, Norway, operates in 30 countries and is the largest supplier of pipeline gas to Europe, alongside being a significant crude oil seller. EQNR's earnings are anticipated to increase by an impressive 120.7% year over year for 2026, accompanied by a 10.5% rise in broker ratings in the past four weeks.